3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
35
Neoplasm Metastasis
7
Ovarian Neoplasms
6
Sarcoma
4
Neoplasms
4
Lymphoma, Non-Hodgkin
4
Pancreatic Neoplasms
3
Multiple Myeloma
3
Lymphoma
3
Glioma
3
Endometrial Neoplasms
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms by Site
2
Medulloblastoma
2
Lymphoma, Mantle-Cell
2
Lung Neoplasms
2
Liposarcoma
2
Leukemia, Myeloid, Acute
2
Histiocytosis, Langerhans-Cell
2
Interventions
belzutifan
3
palbociclib
1
lenvatinib
1
gallium Ga 68 dotatate
1
cabozantinib
1
Nivolumab
1
Everolimus
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
palbociclib
×
90 days
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled